Scancell cleared by FDA for Phase 3 trial

Scancell secured FDA clearance of an IND for a registrational Phase 3 trial of iSCIB1+ in advanced (unresectable stage IIIB/IV) melanoma, with progression-free survival agreed as the surrogate endpoint. The company completed a 140-patient Phase 2 SCOPE study of SCIB1/iSCIB1+ combined with nivolumab and ipilimumab and says the analysis identified a selection marker to enrich Phase 3 responders; iSCIB1+ is a needle-free intramuscular Immunobody intended for patients with selected HLA alleles representing roughly 80% of melanoma cases. The clearance establishes a clear pathway for late-stage development and could materially affect Scancell’s clinical and commercial valuation if Phase 3 confirms the Phase 2 signals for PFS and emerging overall survival.

Analysis

Market structure: IND clearance materially re-risks valuation toward a binary late‑stage outcome for Scancell (AIM:SCLP / OTC:SCNLF / FRA:SCP) and benefits niche players—CMOs, HLA genotyping labs and companies enabling needle‑free IM delivery. The agreed surrogate (PFS) and an HLA selection marker covering ~80% of melanoma patients increase probability of success vs unconstrained vaccine programs, improving implied market share vs historical cancer‑vaccine failures, but real commercial penetration will depend on payers valuing an add‑on to PD‑1/CTLA‑4 combos.

Risk assessment: Tail risks include Phase‑3 negative or safety signals, loss of access to nivolumab+ipilimumab backbone (BMY dependency), or manufacturing/device setbacks; any of these would plausibly crash equity >60%. Immediate: expect headline-driven volatility over days; short term (3–9 months): protocol details, trial start and enrollment pace; long term (12–36 months): pivotal readout and commercialization/payer negotiations.

Trade implications: Size exposure small and option‑leveraged: target initial equity exposure 1–2% of portfolio, scale to 4% only after randomized Phase‑3 start or partnership. Prefer defined‑risk call spreads if listed (12–18 month tenor) or OTC structured notes where options absent; overweight CMOs and diagnostics (contract manufacturing, HLA testing) while underweight late‑stage monotherapy immuno players lacking biomarkers.

Contrarian angles: Market optimism may underweight commercialization frictions—Provenge precedent and payer resistance to add‑on costly biologics are real; HLA selection can introduce enrolment bias that inflated Phase‑2 PFS. If Scancell secures a BMS collaboration or clear interim PFS at 6–12 months the move will be justified; absent that, downside is likely underpriced.

Key Decisions for Investors

• Establish a small long position: allocate 1.5% of portfolio to Scancell (AIM:SCLP or OTC:SCNLF). Set an initial stop‑loss at -40% and plan to scale up to 4% if company announces randomized Phase‑3 start or first patient in within 6 months; trim half at +150% and take profits at +300% on successful Phase‑3 setup or partnership.
• Use options for leveraged, defined risk exposure: purchase a 12–18 month call spread sized to 0.5% notional (long nearer‑term call at ~ATM, short higher strike ~+100–150%) to cap downside and participate in upside; if exchange options unavailable, replicate with 0.5% small equity plus protective put (25–35% OTM, 12 months).
• Rotate sector exposure: overweight CMOs and diagnostics (allocate incremental 1–2% to reputable CMOs and HLA/genotyping plays) and underweight non‑biomarker oncology names. Specific trigger to add exposure: formal partnership with BMS or other major oncology firm announced within 90 days or FDA acceptance of Phase‑3 protocol with interim PFS boundary defined.